| Identification | Back Directory | [Name]
1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- | [CAS]
2403733-82-2 | [Synonyms]
1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- | [Molecular Formula]
C25H27F3N4O4 | [MOL File]
2403733-82-2.mol | [Molecular Weight]
504.5 |
| Hazard Information | Back Directory | [Uses]
GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease[1]. | [in vivo]
GLPG3970 (10 mg/kg; oral administration; twice daily for 5 consecutive days) decreases the ear thickness of murine models of psoriatic-like epidermal hyperplasia induced by intradermal injections of IL-23[1].
GLPG3970 (60 mg/kg; oral administration; twice daily until mice are sacrificed) shows better clinical manifestations compared to vehicle groups in murine collagen-antibody induced arthritis model (CAIA)[1].
GLPG3970 (30 mg/kg; oral administration; twice daily for 7 consecutive days) reduces disease activity index ompared to vehicle groups in mice T cell transfer model[1]. | [References]
[1] DESROY N, et al. NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES. WO/2019/238424. 2019. |
|
|